MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of partnered and internally developed therapeutic candidates. The company’s proprietary ex vivo non-viral cell loading technology is used to modulate and control cell function and overcomes critical obstacles, such as safety and scalability, that are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its enabling technology by outlicensing to four partners for development and commercialization in more than eight therapeutic programs in: oncology, pulmonary, metabolic and infectious diseases. In addition, MaxCyte is developing three drug candidates in collaboration with leading researchers: one in Phase I/II clinical trials for treatment of chronic lymphocytic leukemia (CLL) and two preclinical oncology programs. MaxCyte’s clinical-grade cell loading technology is fully developed and validated with an FDA Master File in place. The technology is RAC cleared and integral to two ongoing Phase I/II trials. Additional programs will soon enter the clinic.

For further information, contact:
Anthony Recupero, Ph.D.
VP Business Development
anthonyr@maxcyte.com

Top^